27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
- Pfizer Inc (NYSE:PFE) has reported a Q4 adjusted EPS of $1.14, up 45% Y/Y, well ahead of the consensus of $1.05.
- The company achieved revenues of $24.29 billion, up 2% and 13% on an operational basis, marginally missing the Wall Street estimate of $24.32 billion.
- For FY22, Pfizer's $100.3 billion revenues are at an all-time high, reflecting 30% operational growth.
- Excluding contributions from Paxlovid and Comirnaty, revenues grew 2% operationally.
- FY23 Outlook: Pfizer forecasts FY23 sales to fall to $67-$71 billion from $100 billion in 2022 versus the consensus of $74.13 billion.
- The company expects adjusted EPS guidance of $3.25-$3.45, down from $6.58 in 2022 and the consensus of $4.44.
- Pfizer expects sales of $13.5 billion from the COVID-19 vaccine for 2023 and projected $8 billion in sales of its antiviral pill, Paxlovid. That compared with sales of $37.81 billion for the vaccine and $18.93 billion for Paxlovid in 2022.
- Price Action: PFE shares are down 2.99% at $42.25 during the premarket session on the last check Tuesday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!